drugset / Trial / NCT01828762
Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
Completed
8 enrolled
Shanghai AbelZeta Ltd.
China Cell Technology Ltd. · collabNo.85 Hospital, Changning, Shanghai, China · collab
NaSingle-groupOpen-labelTreatment
Summary
Although liver resection, liver transplantation, a-interferon, Transarterial Chemo Embolization (TACE), percutaneous ethanol injection (PEI), Percutaneous microwave coagulation therapy (PMCT), Radiofrequency ablation (RFA) provide options to treat patients with HCC, the high recurrence rate of mid-late stage liver cancer still exists. The safety of autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma (HCC) Patients Following Resection and TACE Therapy will be evaluated.
Timeline
- Start
- 2012-12
- Primary completion
- 2013-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ELTRAPULDENCEL-T | Cell therapy | — | Subcutaneous |
| Background | sargramostim | Protein / enzyme biologic | — | Subcutaneous |